Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis

Liu, Mengge; Li, Shiyu; Zhang, Qian; Xu, Zhenrui; Wang, Jiajia; Sun, Han

doi:10.1016/j.intimp.2018.02.004

Cited by 43 publications

(22 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, “designer probiotics” has drawn attention as an innovative approach, where genetically engineered bacteria with specific functionalities are administered to patients[ 112 ]. Promising results were found when recombinant Bifidobacteria were used as carriers for alpha-melanocyte and manganese superoxide dismutase in experimental colitis[ 113 , 114 ]. In recent years, “specific targeting” which allows nutrients or bioactive compounds to reach and target the specific site of inflammation to exert their effects, has become a trending topic of research for IBD control and will be of tremendous importance in future research[ 115 ].…”

Section: Future Trendsmentioning

confidence: 99%

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends

Mijan

Lim

2018

WJG

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a serious health concern among western societies. The disease is also on the rise in some East Asian countries and in Australia. Health professionals and dietitians around the world are facing an unprecedented challenge to prevent and control the increasing prevalence of IBD. The current therapeutic strategy that includes drugs and biological treatments is inefficient and are associated with adverse health consequences. In this context, the use of natural products is gaining worldwide attention. In vivo studies and clinical evidence suggest that well-planned dietary regimens with specific nutrients can alleviate gastrointestinal inflammation by modulating inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin 1 (IL-1), IL-6, IL-1β, and IL-10. Alternatively, the avoidance of high-fat and high-carbohydrate diets is regarded as an effective tool to eliminate the causes of IBD. Many functional foods and bioactive components have received attention for showing strong therapeutic effects against IBD. Both animal and human studies suggest that bioactive functional foods can ameliorate IBD by downregulating the pro-inflammatory signaling pathways, such as nuclear factor κB, STAT1, STAT6, and pro-inflammatory cytokines, including IL-1β, IL-4, IL-6, COX-2, TNF-α, and interferon γ. Therefore, functional foods and diets have the potential to alleviate IBD by modulating the underlying pathogenic mechanisms. Future comprehensive studies are needed to corroborate the potential roles of functional foods and diets in the prevention and control of IBD.

show abstract

Section: Future Trendsmentioning

confidence: 99%

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends

Mijan

Lim

2018

WJG

View full text Add to dashboard Cite

show abstract

“…Other studies have focused on modifying bacteria to produce substances that counteract the action of reactive oxygen species (ROS) (Bruno-Bárcena et al, 2004;Han et al, 2006;Carroll et al, 2007;Watterlot et al, 2010;LeBlanc et al, 2011;del Carmen et al, 2014;Liu et al, 2018). Gastrointestinal tract inflammation has been associated with an overactive immune system and the accumulation of ROS.…”

Section: Constitutive Systemsmentioning

confidence: 99%

“…Most studies involving ROS have genetically modified lactic acid bacteria to be used as delivery vehicles for antioxidants, achieving reduced inflammation in different in vitro and in vivo models. However, one study did utilize the more dominant bacterium, B. longum, to express the antioxidant enzyme manganese superoxide dismutase, reducing DSS-induced colitis in mice (Liu et al, 2018).…”

Section: Constitutive Systemsmentioning

confidence: 99%

Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases

Barra

Danino

Garrido

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Inflammatory intestinal diseases such as Crohn's disease and ulcerative colitis have seen an increase in their prevalence in developing countries throughout the current decade. These are caused by a combination of genetic and environmental factors, altered immune response, intestinal epithelium disruption and dysbiosis in the gut microbiome. Current therapies are mainly focused on treating symptoms and are often expensive and ineffective in the long term. Recently, there has been an increase in our understanding of the relevance of the gut microbiome and its impact on human health. Advances in the use of probiotics and synthetic biology have led to the development of intestinal biosensors, bacteria engineered to detect inflammation biomarkers, that work as diagnostic tools. Additionally, live biotherapeutics have been engineered as delivery vehicles to produce treatment in situ avoiding common complications and side effects of current therapies. These genetic constructs often express a therapeutic substance constitutively, but others could be regulated externally by specific substrates, making the production of their treatment more efficient. Additionally, certain probiotics detecting specific biomarkers in situ and responding by generating a therapeutic substance are beginning to be developed. While most studies are still in the laboratory stage, a few modified probiotics have been tested in humans. These advances indicate that live biotherapeutics could have great potential as new treatments for inflammatory intestinal diseases.

show abstract

“…Therapeutic proteins are gaining increased popularity, due to their low toxicity and minimal nonspecific effect, which allow them increased applicability to multiple disease (Choonara et al ., ; Liu et al ., ). Antimicrobial peptides (AMPs) secreted by intestinal immune, epithelial cells and lymphocytes belong to the important effectors of innate immunity compartment, serving as a first line of the defence against pathogens.…”

Section: Introductionmentioning

confidence: 97%

Oral delivery of pancreatitis‐associated protein by Lactococcus lactis displays protective effects in dinitro‐benzenesulfonic‐acid‐induced colitis model and is able to modulate the composition of the microbiota

Breyner

Boas

Fernandes

et al. 2019

Environmental Microbiology

View full text Add to dashboard Cite

SummaryAntimicrobial peptides secreted by intestinal immune and epithelial cells are important effectors of innate immunity. They play an essential role in the maintenance of intestinal homeostasis by limiting microbial epithelium interactions and preventing unnecessary microbe‐driven inflammation. Pancreatitis‐associated protein (PAP) belongs to Regenerating islet‐derived III proteins family and is a C‐type (Ca+2 dependent) lectin. PAP protein plays a protective effect presenting anti‐inflammatory properties able to reduce the severity of colitis, preserving gut barrier and epithelial inflammation. Here, we sought to determine whether PAP delivered at intestinal lumen by recombinant Lactococcus lactis strain (LL‐PAP) before and after chemically induced colitis is able to reduce the severity in two models of colitis. After construction and characterization of our recombinant strains, we tested their effects in dinitro‐benzenesulfonic‐acid (DNBS) and Dextran sulfate sodium (DSS) colitis model. After the DNBS challenge, mice treated with LL‐PAP presented less severe colitis compared with PBS and LL‐empty‐treated mice groups. After the DSS challenge, no protective effects of LL‐PAP could be detected. We determined that after 5 days administration, LL‐PAP increase butyrate producer's bacteria, especially Eubacterium plexicaudatum. Based on our findings, we hypothesize that a treatment with LL‐PAP shifts the microbiota preventing the severity of colon inflammation in DNBS colitis model. These protective roles of LL‐PAP in DNBS colitis model might be through intestinal microbiota modulation.

show abstract

Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis

Cited by 43 publications

References 48 publications

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends

Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends

Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases

Oral delivery of pancreatitis‐associated protein by Lactococcus lactis displays protective effects in dinitro‐benzenesulfonic‐acid‐induced colitis model and is able to modulate the composition of the microbiota

Contact Info

Product

Resources

About